# Strong constitutive NF-κB signaling in B cells drives SLL/CLL-like lymphomagenesis and overcomes microenvironmental dependencies

**Authors:** Valeria Soberón, Lena Osswald, Andrew Moore, Dominika Sosnowska, Gene Swinerd, Jingyu Chen, Seren Baygün, Carina Diehl, Gönül Seyhan, Laura Kraus, Vanessa Gölling, Ricarda Trapp, Thomas J. O’Neill, Sabrina Bortoluzzi, Daniel Kovacs, Tim Ammon, Pankaj Singroul, Yuliia Hubarzhevska, Rupert Öllinger, Sebastian Mueller, Olga Baranov, Piero Giansanti, Felix Gillhuber, Sonja Grath, Oliver Weigert, Andreas Rosenwald, Yoshiteru Sasaki, Klaus Rajewsky, Katja Steiger, Florian Bassermann, Roland Rad, Daniel Krappmann, Ingo Ringshausen, Marc Schmidt-Supprian

PMC · DOI: 10.1038/s41375-025-02844-8 · Leukemia · 2026-01-16

## TL;DR

Strong NF-κB signaling in B cells causes SLL/CLL-like lymphomas and reduces reliance on the tumor environment.

## Contribution

This study identifies constitutive NF-κB signaling as a driver of lymphomagenesis and shows it reduces microenvironmental dependencies.

## Key findings

- Constitutive IKK2 signaling in B cells dose-dependently induces SLL/CLL-like lymphomas.
- Strong NF-κB activation provides a competitive advantage to B1a cells and synergizes with TCL1 overexpression.
- NF-κB signaling reduces the need for microenvironmental support in TCL1-driven lymphomas.

## Abstract

Aberrant activation of NF-κB transcription factors is a hallmark of human lymphomas. Most lymphoma-intrinsic as well as microenvironment-induced NF-κB activation occurs upstream of the key kinase IKK2, therefore affecting additional pathways. Here, we show that canonical NF-κB signaling in mouse B cells, induced through the expression of one or two copies of a constitutively active IKK2 variant, dose-dependently drives lymphomagenesis. The observed phenotype and stereotypic B cell receptor clonality resemble human small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL). Stronger IKK2 signaling drives early B1a cell expansion and uniform SLL/CLL-like lymphomagenesis, while intermediate signals cause more heterogeneous malignancies. Mechanistically, constitutive IKK2 signals provide a profound cell-intrinsic competitive advantage to B1a cells and dose-dependently synergize with TCL1 overexpression in driving aggressive CLL. Further, strong constitutive NF-κB activation overcomes critical microenvironmental dependencies of TCL1-driven lymphomas. Our findings establish canonical NF-κB as an oncogenic driver in lymphoma and reveal reduced microenvironment dependency as a key NF-κB-mediated mechanism, thus highlighting its therapeutic relevance.

## Linked entities

- **Genes:** IKBKB (inhibitor of nuclear factor kappa B kinase subunit beta) [NCBI Gene 3551], TCL1A (TCL1 family AKT coactivator A) [NCBI Gene 8115]
- **Proteins:** NFKB1 (nuclear factor kappa B subunit 1), IKBKB (inhibitor of nuclear factor kappa B kinase subunit beta)
- **Diseases:** chronic lymphocytic leukemia (MONDO:0004948)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** IKBKB (inhibitor of nuclear factor kappa B kinase subunit beta) [NCBI Gene 3551] {aka IKK-2, IKK-beta, IKK2, IKKB, IMD15, IMD15A}, TCL1A (TCL1 family AKT coactivator A) [NCBI Gene 8115] {aka TCL1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}
- **Diseases:** malignancies (MESH:D009369), lymphoma (MESH:D008223), CLL (MESH:D015451)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12960208/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12960208/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC12960208/full.md

---
Source: https://tomesphere.com/paper/PMC12960208